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Abstract
Significance: Protein neddylation is catalyzed by an E1 NEDD8-activating enzyme (NAE), an E2 NEDD8-
conjugating enzyme, and an E3 NEDD8 ligase. Known physiological substrates of neddylation are cullin family
members. Cullin neddylation leads to activation of cullin-RING ligases (CRLs), the largest family of E3
ubiquitin ligases responsible for ubiquitylation and degradation of many key signaling/regulatory proteins.
Thus, through modulating CRLs, neddylation regulates many biological processes, including cell cycle pro-
gression, signal transduction, and tumorigenesis. Given that NEDD8 is overexpressed and CRLs are abnormally
activated in many human cancers, targeting protein neddylation, in general, and cullin neddylation, in partic-
ular, appears to be an attractive anticancer approach. Recent Advances: MLN4924, a small molecule inhibitor
of NAE, was discovered that inactivates CRLs and causes accumulation of CRL substrates to suppress tumor
cell growth both in vitro and in vivo. Promising preclinical results advanced MLN4924 to several clinical trials
for anticancer therapy. Critical Issues: In preclinical settings, MLN4924 effectively suppresses tumor cell
growth by inducing apoptosis, senescence, and autophagy, and causes sensitization to chemoradiation therapies
in a cellular context-dependent manner. Signal molecules that determine the cell fate upon MLN4924 treatment,
however, remain elusive. Cancer cells develop MLN4924 resistance by selecting target mutations. Future
Directions: In the clinical side, several Phase 1b trials are under way to determine the safety and efficacy of
MLN4924, acting alone or in combination with conventional chemotherapy, against human solid tumors. In the
preclinical side, the efforts are being made to develop additional neddylation inhibitors by targeting NEDD8
E2s and E3s. Antioxid. Redox Signal. 21, 2383–2400.
Introduction: Protein Ubiquitylation and Neddylation
Protein ubiquitylation, catalyzed by the ubiquitin–proteasome system (UPS), is a major clearance system
for the maintenance of protein homeostasis by degrading
unwanted proteins, which include misfolded, damaged, and
short-lived proteins (15, 41). A protein destined for degra-
dation via UPS is marked by a polyubiquitin tag, resulting
from a biochemical process known as ubiquitylation, which
is carried out via a three-step enzymatic cascade (15). First,
ubiquitin is activated in an ATP-dependent reaction by a
ubiquitin-activating enzyme (UAE) (E1) and is then trans-
ferred to a ubiquitin-conjugating enzyme (E2). Finally, a
ubiquitin ligase (E3), which recognizes and recruits a target
protein, designated as the substrate, transfers and conjugates
ubiquitin from the E2 onto a lysine (K) residue on the sub-
strate. Ubiquitin itself contains seven lysine residues, which
serve as the acceptors for the second ubiquitin molecule,
leading to polyubiquitylation of the substrate after multiple
rounds of this reaction. In this process, E3 ubiquitin ligases
perform a critical role through the selective binding of protein
substrates. The human genome encodes 2 E1s, 38 E2s, and
more than 600 E3 ubiquitin ligases, which can be subdivided
into four major classes based on their structural and bio-
chemical features (163). The UPS is abnormally regulated in
many human diseases, particularly in neurodegenerative
diseases and cancers (16, 17). The successful development of
bortezomib (VELCADE), a first-in-class proteasome inhibi-
tor for the treatment of multiple myeloma and relapsed
mantle cell lymphoma (105), demonstrates that the UPS is an
attractive anticancer target.
Protein neddylation is a process of tagging NEDD8 onto a
substrate protein, not for degradation, but for modulation of
protein activity/function. NEDD8 is one of the most studied
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ubiquitin-like (UBL) proteins and is 60% identical and 80%
homologous to ubiquitin (56). Like ubiquitin, NEDD8 is at-
tached to its substrates by an isopeptide linkage between its
C-terminal Gly76 and a lysine residue of the target protein.
However, NEDD8 is first synthesized as a precursor that
contains five additional residues downstream fromGly76 that
need to be cleaved by C-terminal hydrolases, which include
UCH-L3 (52, 71) and NEDP1/DEN1/SENP8 (33, 89, 149).
After this processing, NEDD8 is activated in an ATP-
dependent reaction by an E1 NEDD8-activating enzyme
(NAE). Activated NEDD8 is then transferred to an E2
NEDD8-conjugating enzyme, which shuttles it to an E3 li-
gase and ultimately conjugates NEDD8 to its specific sub-
strates (Fig. 1).
The NEDD8 cascade is known to contain a single E1
(NAE), two E2s (UBE2M, also known as UBC12, and
UBE2F), and a few E3s (see Fig. 1). NAE is a heterodimer,
consisting of NAE1/APPBP1 and UBA3/NAEb (8) and is
structurally and biochemically similar to UAE. NAE1 and
UBA3 are homologous to the amino and carboxyl regions of
UAE, respectively. UBE2M preferentially neddylates RING
box protein-1 (RBX1)-associated cullins (CUL1–3, 4A and
4B), whereas UBE2F promotes neddylation of RBX2-
associated CUL5 (43). Except defective in cullin neddylation
1 (DCN1) (66, 67) and DCN1-like proteins (90), the majority
of NEDD8 E3 ligases contain really interesting new gene
(RING) finger domains, which include RBX1 and RBX2
(also known as regulators of cullins 1 [ROC1] and ROC2/
SAG, respectively) (26, 43, 57), murine double minute-2
(MDM2) (150), casitas B-lineage lymphoma (c-CBL) (108,
170), SCFFBXO11 (3), ring finger protein 1111 (RNF111) (84),
inhibitors of apoptosis (IAPs) (9, 97), Tfb3 (112), and
TRIM40 (100). DCN1 serves as an NEDD8 E3 ligase for
cullin neddylation in Caenorhabditis elegans and Sacchar-
omyces cerevisiae (67). Human cells harbor five DCN1-like
proteins termed DCNL1–DCNL5, which have distinct
N-terminal domains, but share a conserved C-terminal po-
tentiating neddylation (PONY) domain. In yeast, this PONY
domain of DCN1 is necessary and sufficient for cullin ned-
dylation in vivo and in vitro (66). DCNL1–DCNL3 have been
shown to interact with cullins and modulate cullin neddyla-
tion (90). Interestingly, DCN1 does not contain a RING do-
main for its catalytic activity, rather it directly interacts with
the NEDD8 E2 UBE2M on a surface that overlaps with the
E1-binding site (66). A recent structural study showed that
UBE2M is N-terminal acetylated and this N-acetyl-methio-
nine is completely buried in a hydrophobic pocket of DCN1
E3. This interaction promotes cullin neddylation (121).
A reverse process for protein neddylation is protein de-
neddylation. Conjugated NEDD8 is removed from a neddy-
lated substrate by the action of an NEDD8 isopeptidase. The
best characterized NEDD8 isopeptidase is the COP9 signa-
losome complex (CSN), a zinc metalloprotease consisting of
8 subunits. CSN5 is the catalytic subunit of CSN, which
deneddylates cullins (18, 146). NEDP1, a cysteine protease,
is another NEDD8-specific isopeptidase, which also pro-
cesses NEDD8 precursor (40, 116, 122). Additional proteases
with dual specificity for NEDD8 and ubiquitin include
USP21 (37), Ataxin-3 (31), PfUCH54 (4), UCH-L1, and
UCH-L3 (40) (Fig. 1).
Conservation of the Neddylation Pathway
During Evolution
Although NEDD8 was initially identified as a gene that is
downregulated in mouse brain during development (64), it
was soon demonstrated that NEDD8 is detectable in various
mouse tissues and highly conserved in vertebrate species as
well as in yeast (65), suggesting that the neddylation pathway
is essential during species evolution. Indeed, genetic deple-
tion of components of the NEDD8 pathway in Schizo-
saccharomyces pombe (106), C. elegans (53), Drosophila
(107), or in mouse (137) is lethal, demonstrating that the
NEDD8 pathway is essential for the viability of most model
organisms. Interestingly, although an intact NEDD8 pathway
is not essential for cell growth in S. cerevisiae (74), the
combination of pathway mutants with temperature-sensitive
mutants of cdc34 caused lethality (69). Mutations in the
AXR1 and ECR1 genes in Arabidopsis thaliana, the orthologs
of human NAE1 and UBA3, respectively, result in defects in
auxin signaling (111). Moreover, plants deficient in both
AXR1 (E1) and RCE1, the ortholog of NEDD8 E2, show a
FIG. 1. The enzymatic cascades
for protein neddylation and de-
neddylation. Schematic representa-
tion of each step of the NEDD8
conjugation pathway, including NEDD8
precursor processing, NEDD8 activa-
tion by NAE, E2 loading, conjugation
to a substrate by an E3 and recycling
of NEDD8 by a NEDD8 isopeptidase.
The involving enzymes in each step
are listed. NAE, NEDD8-activating
enzyme. To see this illustration in
color, the reader is referred to the web
version of this article at www.liebert
pub.com/ars
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seedling lethal phenotype, a characteristic of defective auxin
signaling (23). Inactivation of the NEDD8 pathway in TS-41
hamster cells expressing a temperature-sensitive mutant of
Smc1, the ortholog of human NAE1, leads to repetitive cycles
of G1/S-phases without entering the G2/M-phase at the
nonpermissive temperature, suggesting an important role
for the NEDD8 pathway in regulating DNA replication,
cell cycle progression, and cell division (38). In addition,
C. elegans embryos expressing a temperature-sensitive mu-
tant of rfl-1, the ortholog of human UBA3, have a myriad of
defects in cytokinesis at a restrictive temperature (68).
In humans, accumulating evidence shows that NEDD8 is
overexpressed in some human diseases such as neurodegen-
erative disorders (24, 96) and cancers (12, 120). Thus, tar-
geting protein neddylation appears to be an attractive
approach for targeted anticancer therapy (143). Indeed,
MLN4924, a newly discovered small molecule inhibitor of
NAE, suppresses tumor cell growth both in vitro and in vivo
(127) and has been advanced to several Phase I clinical trials
against a number of human malignancies (126, 128).
Therefore, it may be very helpful for future drug development
to characterize as to which cellular proteins are neddylated,
how this modification affects their functions, and how this
neddylation is regulated.
Substrates of the Neddylation Pathway
and Associated Biological Processes
Cullin-RING ligases
In contrast to a wide range of ubiquitylated proteins, very
few proteins are known to be neddylated. Table 1 lists most, if
not all, known substrates of the NEDD8 pathway. The best
characterized substrate of the NEDD8 pathway is the cullin
family of proteins (109). In the human genome, there are
Table 1. NEDD8 Pathway Substrates
Substrates E3 ligase Function of neddylation References
Cullins RBX1/2 and/or DCN1 Increases CRL activity 43, 57, 66, 67, 90, 109
p53 MDM2 and SCFFBXO11 Inhibits p53 transcriptional activity 3, 150
p73 MDM2 Inhibits p73 transcriptional activity 142
MDM2 MDM2 Increases Mdm2 stability 150
Ribosomal proteins
(L11, S14)
MDM2 Increases ribosomal protein stability 133, 151, 159
HuR MDM2 Controls the nuclear localization
of HuR and protects it from degradation
30
EGFR c-CBL Enhances the efficiency of EGFR
ubiquitination and facilitates its
degradation
108
TGF-bRII c-CBL Stabilizes TGF-bRII by antagonizing
ubiquitination and degradation
170
HIF1a/HIF2a Increases protein stability 118
BCA3 Recruits histone deacetylase SIRT1
that represses NFjB-dependent
transcription
35
AICD Inhibits AICD-mediated transcriptional
activation via the inhibition of its
interaction with the transcription
coactivators Fe65 and Tip60
72
E2F-1 Reduces E2F-1 stability, transcriptional
activity, and cell growth
80
IKKc TRIM40 Inhibits NF-jB activity 100
SHC Facilitates the formation of a ZAP70-Shc-Grb2
signaling complex and affects downstream
Erk activation
51
Caspases/IAPs/RIP1 IAPs Suppresses caspase activity 9, 97
RCAN1 Increases RCAN1 stability by inhibiting
proteasomal degradation of RCAN1
and increases RCAN1 binding to calcineurin
101
pVHL Prevents pVHL interaction with Cul2-containing
complexes, promotes pVHL association
with fibronectin, and the assembly
of extracellular matrix
130
Parkin/PINK1 Increases parkin E3 ligase activity and stabilizes
PINK1 55 kDa fragment
13, 140
Histone H4 RNF111 Activates DNA damage-induced ubiquitination 84
AICD, APP intracellular domain; BCA3, breast cancer-associated protein 3; c-CBL, casitas B-lineage lymphoma; CRL, cullin-RING
ligase; DCN1, defective in cullin neddylation 1; E2F-1, E2F transcription factor 1; EGFR, epidermal growth factor receptor; HIF1,
hypoxia-inducible factor-1; HIF2, hypoxia-inducible factor-2; HuR, Hu antigen R; IAPs, inhibitors of apoptosis; MDM2, murine double
minute-2; PINK1, PTEN induced putative kinase 1; pVHL, von Hippel-Lindau protein; RCAN1, regulator of calcineurin 1; RING, really
interesting new gene; RNF111, ring finger protein 111; TGFb-RII, transforming growth factor b type II receptor.
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eight cullin family members, including Cul-1–3, 4A, 4B, 5, 7,
and Cul-9, also known as PARC, with an evolutionarily
conserved cullin homology domain (CH domain with*150
amino acids) at the C-terminus. Each cullin protein acts as a
molecular scaffold that binds to an adaptor protein and a
substrate receptor protein at the N-terminus, and a RING
protein, RBX1 or RBX2 at the C-terminus to assemble cullin-
RING ligases (CRLs), the largest family of E3 ubiquitin li-
gases. By promoting ubiquitylation and degradation of a
variety of key substrates, CRLs control many important bi-
ological processes, including cell cycle progression, DNA
repair, signal transduction, gene transcription, embryonic
development, genomic integrity, and tumorigenesis [for re-
cent review, see Ref. (163)]. Each individual cullin contains a
key lysine residue at its C-terminus for targeted NEDD8
modification, which is required for the CRL activity. RBX1
and RBX2 in conjunction with UBE2M and UBE2F, re-
spectively (43, 57), promote cullin neddylation. Recently,
DCN1 and DCNL1–DCNL3 proteins were also found to act
as NEDD8 E3 ligases for cullins (66, 67, 90).
Cullin neddylation is a process known to activate CRLs,
thus promoting the ubiquitylation of their protein substrates.
In an inactive mode, cullin-associated and neddylation-
dissociated-1 (CAND1) binds to non-neddylated cullins and
blocks the binding of cullins to the substrate receptor–adaptor
module via its N-terminus. Neddylation of cullins disrupts
this inhibitory binding by CAND1 and retains the CRLs in an
active conformation (28, 36, 57, 78, 152, 166), which (i)
increases and stabilizes the recruitment of ubiquitin-charged
E2 to CRLs (119), (ii) bridges an *50 A˚ gap between the
substrate-docking site and the E2-active site (167), which
greatly facilitates the initiation of ubiquitin transfer (119),
and (iii) enhances the rate of ubiquitin chain elongation,
suggesting that this conformation change also improves the
activated E2 access to the end of the nascent polyubiquitin
chain (119, 124) (Fig. 2).
The mechanism, by which cullin neddylation enhances the
transfer of ubiquitin (Ub) from ubiquitin charged E2 to the
substrate, is fully illuminated by crystal structures of the C-
terminal domain (CTD) of CUL5 bound to RBX1 in the
unmodified and NEDD8-conjugated states (28). Neddylation
induces striking conformational rearrangements in CUL5CTD-
RBX1, which eliminates the CAND1 binding site and re-
leases the RBX1 RING domain from its tight cullin binding
into an open conformation. Although the RING domain still
is tethered to CUL5CTD, the linker is more flexible and
readily bridges the*50 A˚ gap between the E2-active site and
naked substrate present in the original CRL complex struc-
ture, which explains why neddylation promotes the initial
ubiquitin transfer. This flexibility also facilitates access of the
activated E2 to the end of the nascent ubiquitin chain, al-
lowing efficient polyubiquitylation (21, 22, 113) (Fig. 2).
Upon polyubiquitylation, the substrate is separated from
the CRL complex, and the COP9 signalosome complex
(CSN) then binds to neddylated cullins and removes NEDD8
from cullins in a reaction known as deneddylation (83). De-
neddylated cullins bind to CAND1, which keeps the CRLs
in an inactive conformation (Fig. 2). Thus, neddylation
promotes the assembly of active CRL E3 complexes and
stimulates the ubiquitination of substrates, whereas de-
neddylation promotes the dissociation of CRL E3 complexes
and potentiates cullin binding with inhibitory CAND1. Dy-
namic neddylation and deneddylation of cullins facilitate the
recycling of the cullin-RING core, making it available for
assembly with other members of CRLs permitting the ubi-
quitination of many different substrates in a short time as
required by the cell to maintain cellular homeostasis (79).
Accumulating data suggest that mutations in the components
of the COP9 signalosome (CSN) lead to defects in cell cycle
progression, signal transduction, and development (5, 6,
147). Thus, it is very important to understand mechanistically
how neddylation and deneddylation are precisely regulated
FIG. 2. Dynamic regulation of
CRL activity by neddylation and
deneddylation. The binding of un-
modified cullin to CAND1 inhibits the
cullin binding to the substrate recep-
tor–adaptor module at its N-terminus.
Neddylation of cullin disrupts the
inhibitory binding by CAND1 and
retains the CRL in an active confor-
mation to promote substrate ubiquity-
lation. After dissociation of
polyubiquitylated substrate from the
CRL complex, CSN binds to the ned-
dylation site of cullin and removes
NEDD8 from cullin for recycling.
CAND1 then binds to cullin and inac-
tivates CRL. CAND1, cullin-associated
and neddylation-dissociated-1; CRL,
cullin-RING ligase; CSN, COP9 sig-
nalosome complex; RING, really inter-
esting new gene. To see this illustration
in color, the reader is referred to the
web version of this article at www
.liebertpub.com/ars
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under physiological conditions or in response to both internal
and external stimuli.
Other noncullin NEDD8 substrates
In addition to cullin family members, which are the known
physiological substrates of neddylation (113), several cellu-
lar proteins are also reported to be neddylated, although a
more rigorous validation by, for example, the NAE inhibitor
MLN4924 is still necessary.
p53. The stability and function of the p53 tumor sup-
pressor is tightly regulated by post-translational modifica-
tions, including ubiquitylation and neddylation, in which the
MDM2 oncoprotein plays a critical role. Acting as a major
ubiquitin E3 ligase, MDM2 promotes p53 polyubiquitylation
and proteasomal degradation with its physiological relevance
demonstrated by the full rescue of embryonic lethality in
Mdm2-null mice by the loss of p53 (20, 55). Significantly,
MDM2 also promotes p53 neddylation, which inhibits the
p53 transactivation activity (150). A mutational analysis of
the RING finger domain of MDM2 showed that mutations,
which affect the ubiquitin ligase activity of MDM2, also af-
fect its Nedd8 ligase activity (123). These findings therefore
provide a strong piece of evidence that MDM2 is a common
component of the ubiquitin and NEDD8 conjugation path-
way. However, there is also evidence to suggest that
MDM2-mediated ubiquitylation and neddylation of p53 are
differentially regulated and elicit different effects on p53.
First of all, MDM2-mediated p53 ubiquitylation required six
lysine residues in the C-terminus of p53 (Lys370, Lys372,
Lys373, Lys381, Lys382, and Lys386), whereas neddylation
only required three lysine residues (Lys370, Lys372, and
Lys373) (150). Second, endogenous p53 in response to UV-
induced DNA damage showed a differential pattern of
modification by ubiquitin and NEDD8 (150). Third, the
Tip60 acetyl-transferase, a known regulator of the MDM2-
p53 axis, was shown to preferentially inhibit MDM2-medi-
ated p53 neddylation, but not ubiquitylation (25). Finally, the
p53-Ub fusion protein promotes the cytoplasmic localization
of p53, whereas the p53-NEDD8 fusion protein has little
effect on nuclear export. Despite the difference in subcellular
localization, both the p53-Ub and p53-NEDD8 fusion pro-
teins retain similar transcriptional activity and both induce
apoptosis at a similar level to nonfused p53 (11). In addition
to MDM2, SCFFBXO11, a CRL E3 ligase, was found to di-
rectly bind to p53 that unexpectedly promoted p53 neddy-
lation rather than ubiquitylation. Consistent with an
inhibitory role of p53 neddylation, SCFFBXO11 suppresses the
p53 transcriptional activity (3).
p73 and MDM2. p73, a member of the p53 family, is also
subject to neddylation by MDM2 E3 (142). MDM2 promotes
the neddylation of TAp73 (full-length), but not DNp73
(N-terminally truncated with N-terminal MDM2-binding
domain deleted), leading to accumulation of TAp73 in the
cytoplasm, thus suppressing its transactivation activity (142).
Interestingly, MDM2 can also catalyze self-neddylation in a
manner similar to its autoubiquitylation (150). However,
unlike MDM2 autoubiquitylation, which destabilizes it,
MDM2 autoneddylation was shown to increase its protein
stability (144). Furthermore, NEDP1, identified as a chemo-
therapy-induced isopeptidase, deneddylates MDM2, leading
to MDM2 destabilization with concomitant p53 activation.
Likewise, knockdown of endogenous NEDP1 stabilized
MDM2, decreased p53, and increased chemoresistance of
cancer cells (144).
Ribosomal proteins. Several ribosomal proteins have
been identified as potential NEDD8 substrates (151). L11 was
found to be neddylated by Mdm2 and deneddylated by
NEDP1 (133). Under nucleolar stressed conditions, L11
neddylation was reduced, which triggered relocalization of
L11 from the nucleolus to the nucleoplasm.MDM2-mediated
L11 neddylation protects L11 from degradation, a process
required for p53 stabilization during nucleolar stress (133).
Thus, neddylation regulates both the subcellular localization
and stability of L11. A recent study showed that the MDM2/
NEDP1 pair also regulates the neddylation and deneddylation
cycle of the ribosomal protein S14, where neddylation causes
protein stabilization and modulates the subcellular localiza-
tion (159). Given that both L11 (81, 160) and S14 (169) bind
to MDM2 and regulate p53 stability, the neddylation–
deneddylation cycle of L11 and S14 by the MDM2/NEDP1
pair adds another layer of control of the MDM2/p53 axis to
ensure precise regulation of p53 protein levels.
Other cellular proteins. With the advancement of detec-
tion technologies, many additional neddylated proteins have
been identified, along with some of their corresponding E3s.
Table 1 provides a relatively comprehensive listing of these
neddylated proteins, known E3s for their neddylation, and the
functional consequences of neddylation. Examples include
(i) Hu antigen R (HuR), a central RNA-binding protein,
highly abundant in many cancers (2), neddylated by Mdm2
(30), (ii) receptor proteins, such as EGFR (108), and trans-
forming growth factor (TGF)-b type II receptor (170), ned-
dylated by the c-Cbl E3, (iii) transcriptional regulators such
as HIF1a/HIF2a (118), breast cancer-associated protein 3
(BCA3) (35), APP intracellular domain (AICD) (72), and
E2F-1 (80), (iv) signaling molecules such as inhibitor of jB
kinase gamma (IKKc) neddylated by TRIM40 (100), cas-
pases neddylated by IAP (9), Shc (51), and regulator of cal-
cineurin 1 (RCAN1) (101), (v) E3 ubiquitin ligases, such as
von Hippel-Lindau (VHL) tumor suppressor (130) and Par-
kin/PINK1 (13, 140), and (vi) finally, histone H4 neddylated
by RNF111 (84). Taken together, these studies suggest that
neddylation plays a role beyond cullin modification and
associated protein degradation. However, given that these
studies were mainly conducted using in vitro biochemical
and cell culture systems, the physiological relevance and
biological significance of these neddylation modifications
await thorough validation by in vivo animal models or in
human cancer specimens.
The Regulation of Redox Homeostasis by Neddylation
The accumulation of damaging reactive oxygen species
(ROS) contributes to a number of pathologies in various
human diseases, including cancer (32, 131). ROS levels,
therefore, need to be tightly controlled to prevent oxidative
stress-induced damages (131). The transcription factor nu-
clear factor erythroid 2-related factor 2 (NRF2) functions as a
master regulator of redox homeostasis by inducing the
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transcription of a wide array of genes involved in defense
against ROS to restore intracellular redox homeostasis (59).
Indeed, nearly all NRF2 target genes contain a consensus
DNA binding motif (RGTGACNNNGC, where R represents
purine and N represents any base) in their promoter region
designated as the antioxidant response element (ARE) (44,
117). The ARE is required for NRF2 binding and subsequent
transcriptional activation of several antioxidant enzymes
(59). By modulation of the cellular levels of NRF2, a well-
established substrate of CRL1 and CRL3 E3 ligases, the
neddylation process, which activates the CRL activity via
cullin neddylation, effectively regulates redox homeostasis
(14, 114, 115, 141, 158) (Fig. 3).
Under a normal unstressed redox environment, the NRF2
level is very low due to targeted ubiquitylation and degra-
dation by two CRL E3s. First, NRF2 is trapped in the cyto-
plasm by binding to its inhibitor, Kelch-like ECH-associated
protein 1 (Keap1), which recruits Cul3 E3 ligase (CRL3), and
targets NRF2 for proteasomal degradation. Second, NRF2 is
phosphorylated by glycogen syntase kinase 3 (GSK3) on the
serine residues with the beta-transducin repeat containing
protein (bTrCP) binding motif (DSGIS), which facilitates
bTrCP-NRF2 binding and subsequent NRF2 degradation by
SCFbTrCP E3 ligase (also known as CRL1) (14, 114, 115).
Under the initial phase of oxidative stresses, there are at least
three mechanisms by which ROS triggers NRF2 accumula-
tion: (i) ROS oxidizes the cysteine residues on Keap1 to
change its conformation, which disrupts the Keap1-NRF2
binding and subsequent NRF2 degradation (44), (ii) ROS
inhibits several phosphatases to activate AKT, which se-
quentially phosphorylates and inactivates GSK3 (138) lead-
ing to abrogation of NRF2 phosphorylation and subsequent
bTrCP binding and CRL1 degradation (14, 114, 115), and
(iii) ROS causes oxidative inactivation of the catalytic cys-
teine residue on Ubc12, the NEDD8-conjugating enzyme
(62, 63), resulting in cullin deneddylation and CRL inacti-
vation. Accumulated NRF2 then translocates to the nucleus,
where it becomes transcriptionally active by binding with one
of the Maf proteins and induces the transcription of phase II
antioxidant enzymes, which deactivate ROS (44). In the late
phase of oxidative stresses when ROS levels decline, AKT is
inactivated by ceramide-activated phosphatases or by other
mechanisms (87) with subsequent activation of GSK3, re-
sulting in SCFbTrCP E3-mediated NRF2 degradation (14, 114,
115). Consequently, NRF2 returns to its basal levels and the
intracellular redox balance is restored (Fig. 3). It is note-
worthy that a wide variety of somatic mutations of Keap1 and
NRF2 are found in human cancers and these mutations dis-
rupt Keap1-mediated negative regulation of NRF2, resulting
in constitutive activation of NRF2 (39, 129). Activated NRF2
is associated with resistance to standard chemotherapy and
poor survival of cancer patients (39, 129), indicating that
NRF2 also has oncogenic functions.
Interestingly, the neddylation inhibitor MLN4924 can ei-
ther decrease or increase the generation of intracellular levels
of ROS. On one hand, through inactivation of CRLs,
MLN4924 causes NRF2 accumulation (99, 127, 145) to
scavenge ROS. On the other hand, through inactivation of
NFjB,MLN4924 generates ROS, which is required for DNA
damage-induced apoptosis (99, 134). Thus, the net outcome
FIG. 3. Redox regulation of NRF2 via CRL E3s: Under normal physiological conditions, the NRF2 level is kept low as
a result of targeted degradation by (i) CRL3 upon Keap1 binding and (ii) CRL1 upon b-TrCP binding, following GSK3-
mediated NRF2 phosphorylation. Under oxidative stressed conditions, ROS on one hand inhibits cullin neddylation to
inactivate CRLs and on the other hand activates AKT to block GSK3-mediated NRF2 phosphorylation, leading to sup-
pression of NRF2 degradation. Accumulated NRF2 then translocates into the nucleus, where it complexes with MAF to bind
to the ARE and transactivates the expression of antioxidant enzymes to scavenge ROS. ARE, antioxidant response element;
GSK3, glycongen synthase kinase 3; Keap1, Kelch-like ECH-associated protein 1; NRF2, nuclear factor erythroid 2-related
factor 2; ROS, reactive oxygen species. To see this illustration in color, the reader is referred to the web version of this
article at www.liebertpub.com/ars
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of neddylation effects on ROS generation is likely to be cell-
type dependent and context dependent. To date, our under-
standing of how neddylation regulates redox homeostasis is
mainly through the modulation of CRL activity (141). Future
studies should be directed toward exploring other potential
mechanisms, including investigation of whether the proteins
involved in redox homeostasis are direct neddylation targets
and if so, under what physiological and/or pathological
conditions they are neddylation, and whether and how ned-
dylation affects their functions.
Targeting Neddylation Pathway for Anticancer Therapy
MLN4924 is a newly discovered investigational inhibitor of
the NAE (127) (Fig. 4A) currently under clinical development.
As an adenosine sulfamate derivative, MLN4924 forms an
MLN4924-NEDD8 adduct catalyzed by NAE. With tight
binding to the NAE-active site, thisMLN4924-NEDD8 adduct
resembles adenylated NEDD8, the first intermediate in the
NAE reaction cycle, and thus prevents subsequent in-
traenzyme reactions and blocks the NAE enzymatic activity
(10). Given that there is only one NAE known to catalyze this
first step of the neddylation reaction, its inhibitor MLN4924
should block the entire neddylation pathway. Indeed, we found
that MLN4924 effectively inhibits neddylation of multiple
cullins, the only known physiological substrates (21, 113), as
evidenced by complete deneddylation of all cullins tested,
including Cul1–Cul3, Cul4A, Cul4B, and Cul5 after 6 h of
treatment in SK-BR3 breast cancer cells (Fig. 4B) (10). Given
that cullin neddylation is required for the activity of CRLs,
whereas CRLs are abnormally activated in human cancers (49,
163), MLN4924, by blocking cullin neddylation, inactivates
the entire family of CRL E3 ligases and serves as a first-in-
class agent, which suppresses tumor cell growth in preclinical
models via multiple mechanisms described below.
MLN4924 induces apoptosis
MLN4924 was first reported in 2009 as a potent growth
suppressing agent against a variety of cancer cell lines
derived from solid tumors (colon and lung) and hematological
malignancies (myeloma and lymphoma) both in in vitro cell
culture and in in vivo xenograft models (127). Subsequent
studies showed that MLN4924 effectively induces apoptosis
in leukemia (91, 93, 125, 127, 134), hepatocellular (82), and
Ewing sarcoma cells (85). Consistent with these findings,
MLN4924 also induces apoptosis in breast cancer cells
(MCF7), as evidenced by increases in the cleaved forms of
PARP and caspase-7 (Fig. 5A). MLN4924-induced apoptosis
is mediated by several mechanisms, all involving accumu-
lation of CRL substrates. First, by inactivating CRL1SKP2 and
CRL4CDT2, which promote chromatin licensing and DNA
replication factor 1 (CDT1) degradation (42, 73), MLN4924
caused accumulation of CDT1 to trigger DNA re-replication
and S phase arrest, ultimately leading to induction of apo-
ptosis (76, 91, 127). A recent genomewide siRNA screen
revealed that induction of apoptosis by MLN4924 involves
multiple DNA damage response (DDR) pathways beyond
those involving CDT1 stabilization (7). Second, by inhibiting
CRL1b-TrCP, MLN4924 causes accumulation of IjBa to
block nuclear factor-jB (NF-jB) activation (148), resulting
in apoptosis induction (93, 134). Third, by inactivating SAG/
RBX2-associated CRLs (50), MLN4924 causes accumula-
tion of proapoptotic NOXA, a known p53 target gene, re-
sulting in apoptosis in some settings (135, 145). Indeed, we
found that CDT1, pIjBa, and NOXA were all accumulated
significantly after MLN4924 treatment to induce apoptosis in
MCF7 cells (Fig. 5A).
MLN4924 induces autophagy
Recently, we found that in addition to apoptosis, MLN4924
also effectively induced autophagy in a concentration- and
time-dependent manner in multiple human cancer cell lines
derived from carcinomas of the breast, colon, liver, brain,
and cervix, indicating that it is likely a universal phenomenon
in cancer cells (82, 164). As an example, shown in Figure 5,
MLN4924 significantly induced punctate structures, a well-
defined surrogate for autophagy (94), in EGFP-LC3-expressing
FIG. 4. MLN4924 as an inhibitor of NAE. (A) Chemical structure of MLN4924. (B)MLN4924 blocks neddylation of all
cullins tested. SK-BR3 cells were treated with 1lM MLN4924 or DMSO vehicle control for the indicated time periods,
followed by western blotting with the indicated antibodies.
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MDA-MB231 cells (Fig. 5B). Furthermore, autophagosomes
were readily detectable by electron microscopy in SK-BR3
cells upon MLN4924 exposure (Fig. 5C). Finally, MLN4924
induction of autophagy was biochemically demonstrated by a
time-dependent conversion of LC3-I to LC3-II and degrada-
tion of p62, two well-established biomarkers of autophagy
(94) in SK-BR3 cells (Fig. 5D, top panels). Our detailed
mechanistic studies revealed that MLN4924-induced autop-
hagy is mainly caused by inactivation of mammalian target of
rapamycin complex 1 (mTORC1), as evidenced by reduced
phosphorylation ofmTOR itself and twomTORC1 substrates,
S6K1 and 4E-BP1 (Fig. 5D, middle panels). mTORC1 inac-
tivation is likelymediated by accumulation of (i) DEP domain
containing mTOR interacting protein (DEPTOR), a naturally
occurring inhibitor of mTORCs (110) and a recently charac-
terized substrate of CRL1b-TrCP (27, 34, 165) and (ii) HIF1a, a
well-known substrate of CRL2VHL (45, 46), followed by ac-
tivation of the HIF1-REDD1-TSC1 axis (164) (Fig. 5D, bot-
tom panels). We further demonstrated that mTORC1
inactivation and subsequent autophagy induction act as an
overall survival signal, since abrogation of autophagy via
genetic and pharmacological means led to an increased sup-
pression of tumor growth by enhancing apoptosis induction
(153, 155, 164). Thus, our findings provide proof-of-concept
FIG. 5. MLN4924 suppresses tumor cell growth via inducing apoptosis, autophagy, and senescence. (A) Induction of
apoptosis: MCF7 cells were treated with 1lM MLN4924 for the indicated time periods, followed by western blotting with
the indicated antibodies. (B–D) Induction of autophagy:MDA-MB231 cells stably expressing EGFP-LC3 were treated with
1 lM MLN4924 or DMSO vehicle control for 24 h and 48 h before photography under a fluorescent microscope (B).
Detection of autophagosomes by electron microscopy (EM). SK-BR3 cells were treated for 24 h with MLN4924 (1 lM),
along with DMSO vehicle control, followed by the EM analysis. Autophagosomes (arrows) are indicated in MLN4924-
treated cells (C). SK-BR3 cells were treated with MLN4924 (1lM), along with DMSO vehicle control for the indicated
time periods, followed by western blotting using the indicated antibodies (D). (E, F) Induction of senescence: SK-BR3 cells
were treated with MLN4924 (1 lM) for 8 h and stained with b-Gal after the drug washout for 72 h (E). SK-BR3 cells were
treated with 1lM MLN4924 for the indicated time periods, followed by western blotting with the indicated antibodies (F).
To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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evidence supporting further investigation of a combination of
MLN4924 with an autophagy inhibitor (155, 162, 164).
MLN4924 induces senescence
In addition to induction of apoptosis and autophagy, we
and others showed that MLN4924 can also induce irrevers-
ible senescence in multiple cancer cell lines (48, 76, 77). We
further show here that MLN4924 treatment induces charac-
teristics associated with senescence in SK-BR3 breast cancer
cells, as evidenced by enlarged and flattened cellular mor-
phology and positive staining of senescence-associated b-Gal
(Fig. 5E). Mechanistic studies revealed that senescence oc-
curs in p21-dependent manner (48), which is logical given
that p21 is a known substrate of CRL1SKP2 (157) and
CRL4CDT2 (1, 61). Although it was shown that senescence
induced by MLN4924 is independent of the pRB/p16 axis in
HCT116 cells (48), p16, along with p21 and p27, was re-
markably induced in response to MLN4924 in SK-BR3 cells
(Fig. 5F), indicating that the role of p16 in senescence could
be cell-type dependent.
MLN4924 as a potential sensitizer
to chemotherapy and radiation
In addition to suppressing tumor cell growth as a single
agent via the mechanism described above, a number of recent
studies have shown that MLN4924 could sensitize a variety
of otherwise resistant cancer cells to chemotherapeutic and
biological agents. For example, we found that MLN4924
sensitized leukemia cells to retinoic acid-induced apoptosis
via accumulation of c-Jun and NOXA (135). MLN4924 also
sensitized head and neck cancer cells to TRAIL-induced
apoptosis through promotion of c-FLIP degradation (161).
Moreover, MLN4924 significantly increased the efficacy of
cisplatin against cisplatin-resistant ovarian cancer cells by
enhancing DNA damage and oxidative stress, and by in-
creasing the expression of the proapoptotic protein, Bcl-2-
interating killer (BIK) (99), as well as by inactivating CRL3
(47). MLN4924 was also shown to increase cellular sensi-
tivity to DNA interstrand crosslink inducing agents, such as
mitomycin C and hydroxyurea in several cancer cell lines
derived from carcinomas of the cervix (HeLa) and colon
(HCT116) by a mechanism involving the suppression of
DNA damage-induced FANCD2 monoubiquitylation and
CHK1 phosphorylation (58). Finally, we tested the combi-
nation of MLN4924 with gemcitabine, a standard chemo-
therapy in pancreatic cancer (95) in two pancreatic cancer
cell lines. Our unpublished data showed that MLN4924 sig-
nificantly sensitized pancreatic cancer cells to gemcitabine.
We also determined the radiosensitizing activity of
MLN4924 in pancreatic cancer cells and found that
MLN4924 effectively inhibited cullin neddylation and sen-
sitized pancreatic cancer cells to ionizing radiation both in
in vitro cell culture and in in vivo xenograft models (145).
Mechanistic studies revealed that MLN4924 treatment in-
duced an accumulation of several CRL substrates, including
CDT1, WEE1, and NOXA, in parallel with an enhancement
of radiation-induced DNA damage, aneuploidy, G2/M phase
cell cycle arrest, and apoptosis. Importantly, knockdown of
accumulated CDT1 or WEE1 partially rescued MLN4924-
mediated radiosensitization, indicating their causal roles
(145). We further found that MLN4924 radiosensitization
can also be observed in few breast cancer cell lines with
mechanisms involving p21 accumulation (154). Thus,
MLN4924 is a potent sensitizer to gemcitabine and radiation,
two clinically used standard therapies for the treatment of
pancreatic cancer patients.
Taken together, accumulated data, including our own
studies, clearly demonstrate that MLN4924 effectively in-
hibits tumor cell growth by inducing all three common types
of death, namely apoptosis, autophagy, and senescence, as
outlined in Figure 6. Induction of apoptosis, as often seen in
both hematologic cancer and solid tumor cells (82, 88, 91, 93,
127, 134, 135, 164), is mainly caused by (i) NF-jB inacti-
vation, resulting from IjBa accumulation, (ii) accumulation
of proapoptotic NOXA, and (iii) DDR, resulting from CDT1
accumulation. On the other hand, induction of autophagy,
mainly seen in solid tumor lines (82, 164), is largely mediated
by inactivation of mTORC1, resulting from accumulation of
DEPTOR and HIF1a. Induction of senescence, also generally
observed in solid tumor cells, is mainly mediated by p21
accumulation (48). Accumulation of p27 and p16 may also
contribute to MLN4924-induced senescence at least in SK-
BR3 cells (Fig. 5F). It is noteworthy that in response to
MLN4924 treatment, cancer cells are subjected to one or
multiple types of death dependent on their own molecular
characteristics. For example, in SK-BR3 breast cancer cells,
MLN4924 preferentially induces autophagy and senescence,
but not apoptosis (Fig. 5F). Thus, these various effects of
MLN4924 can be seen in different cancer cell lines, but not
all of them would co-occur in every setting. Finally,
MLN4924 renders multiple cancer cell lines sensitive to
chemotherapy and radiation therapy with mechanisms
FIG. 6. A model for suppression of cancer cell growth
and sensitization of chemo- and radiation therapies by
MLN4924 (see text for description). To see this illustration
in color, the reader is referred to the web version of this
article at www.liebertpub.com/ars
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mainly involving enhanced DNA damage and subsequent
induction of apoptosis (Fig. 6).
MLN4924 as a Tool in Identification
and Validation of Novel CRL Substrates
Improvements in mass spectrometry methodology and in-
strumentation are likely to facilitate the discovery of addi-
tional CRL substrates. Stable isotope labeling with amino
acids in cell culture (SILAC) presents one such advancement,
which has been validated as a promising approach to quanti-
tate protein abundance (86, 103, 104) and has been used to
study a wide range of cellular protein responses in entire or-
ganisms and even in human tissues, including identification of
protein/DNA interaction partners, protein post-translational
modifications, subcellular protein localization, and changes in
protein levels resulting from drug treatments, stress responses,
and tumorigenesis (19, 102). Thus, SILAC may serve as a
very attractive approach to identify CRL substrates affected
by MLN4924. Indeed, a modified SILAC technique in com-
bination with a diGly monoclonal antibody (which recognizes
the cleaved C-terminal of the Arg-Gly-Gly sequence in ubi-
quitin) has been used to systematically and quantitatively
assess the ubiquitin modified proteome, including neddyo-
mics (60). The SILAC technique was also used to identify
many regulatory proteins as potential novel CRL substrates in
A375 melanoma cells treated with MLN4924 (75), followed
by validation of MRFAP1 as a true CUL4B substrate (70).
Most significantly, both genetic (dominant negative cullins)
and pharmacologic (MLN4924) approaches and techniques,
including cullin inactivation, coupled with genetic assays (or
GPS for global protein stability profiling) (156) and SILAC-
MS-based proteomics (or QUAINT for quantitative ubiqui-
tylation interrogation) were used to identify hundreds of
proteins whose stabilities or ubiquitylation status are con-
trolled by CRLs (29). Through these approaches, the authors
identified and validated NUSAP1 as a CRL1CyclinF substrate,
which is degraded in response to UV radiation and is re-
sponsible for resistance to antitubulin therapeutics (29).
Clinical Development of MLN4924 as a Novel Class
of Anticancer Drug
With promising anticancer activity in preclinical models,
MLN4924 has been in clinical investigation sinceMay, 2008.
Up to now, there are a total of seven Phase I/II clinical trials
for MLN4924 in patients with leukemia, lymphoma, mela-
noma, and several solid tumors (http://clinicaltrials.gov/ct2/
show?term =MLN4924&rank = 1) designed with three main
trial goals: (i) drug safety and tolerability, (ii) drug pharma-
cokinetic parameters, and (iii) disease response rate (Table 2).
The dosing schedules, major toxicities, and disease re-
sponse rate have been recently reviewed for the first four
earlier trials (98). In general, MLN4924 was administrated
via 60-min intravenous infusion on various daily schedules of
21-day cycles (98). The pharmacokinetics of MLN4924
(www.eventureonline.com/eventure/publicAbstractView.do?
id= 193668&congressId= 5650; www.eventureonline.com/
eventure/publicAbstractView.do?id = 193419&congressId =
5650; http://mct.aacrjournals.org/cgi/content/meeting_abstract/
10/11_MeetingAbstracts/A38?sid= f99baff2-718b-4552-8e41-
c9b9570eb9ff) in plasma or tissue was conducted in serial
blood samples, bone marrow aspirates (BMAs), skin punch
biopsies, or fine-needle tumor biopsies collected at 3–6 h
following a weekly drug dosing. The samples were analyzed
by immunohistochemical staining to measure the MLN4924-
NEDD8 covalent adduct and expression of CRL substrates,
such as CDT1, NRF2, and pIjBa as the biomarkers. The
presence of drug was demonstrated by detecting (i)
MLN4924-NEDD8 adducts in the BMAs of all 21 patients
receiving the drug (www.eventureonline.com/eventure/pub-
licAbstractView.do?id= 193668&congressId = 5650) and in
100% of the postdose tumor biopsies (http://mct.aacrjournals
.org/cgi/content/meeting_abstract/10/11_MeetingAbstracts/
A38?sid = f99baff2-718b-4552-8e41-c9b9570eb9ff), and (ii)
increased levels of pIjBa- and Nrf-2-regulated gene tran-
scripts in peripheral blood mononuclear cells (www.even
tureonline.com/eventure/publicAbstractView.do?id= 193419
&congressId = 5650) and CDT1/NRF2 in skin and tumor
biopsies with persistence of up to 24 h (www.eventureonline
.com/eventure/publicAbstractView.do?id= 193419&congress
Id= 5650; http://mct.aacrjournals.org/cgi/content/meeting_
abstract/10/11_MeetingAbstracts/A38?sid = f99baff2-718b-
4552-8e41-c9b9570eb9ff). The major side effects reported
include fatigue, nausea, vomiting, diarrhea, anemia, neu-
tropenia, and elevated liver enzymes (98). In term of disease
response rate, a complete response was seen in four acute
myelogenous leukemia (AML) patients, a partial response
in one Hodgkin’s lymphoma, and one melanoma patient.
Nine melanoma patients had prolonged stable disease (98).
Since 2011, three MLN4924 combinational phase 1b/2 trials
have been launched (http://clinicaltrials.gov/ct2/show?term=
MLN4924&rank= 1). The first trial is for the treatment of
large B-cell lymphoma patients in combination with EPOCH-
R chemotherapy; the second is for patients with end stage solid
tumors in combination with docetaxel, gemcitabine, and pac-
litaxel plus carboplatin; and the third one is for adult AML
patients in combination with azacitidine (Table 2). Upon
completion, these trials will demonstrate the tolerability of
MLN4824 in combination with standard chemotherapies and
should begin to suggest the potential therapeutic effective-
ness ofMLN4924 in combination treatment strategies against
deadly human cancers.
Conclusions and Future Perspectives
In summary, the NEDD8 pathway is being validated as a
potential anticancer target, mainly because the pathway is
overactivated in a number of human cancers (143) and its
inactivation by the first-in-class NAE inhibitor, MLN4924,
suppresses tumor growth in many preclinical models. Whe-
ther MLN4924 will mature to an FDA approved first-in-class
anticancer drug will depend on the results of ongoing clinical
trials. MLN4924 is anticipated to be less toxic than the FDA
approved proteosome inhibitors such as bortezomib and
carfilzomib, since MLN4924 selectively blocks degradation
of a specific set of cellular proteins regulated by CRLs,
whereas bortezomib inhibits degradation of all proteins
through inhibition of the 26S proteasome (105). However,
tumor cell selectivity issues still exist for MLN4924. First of
all, given that CRL activity is required for proliferation,
differentiation, and survival of normal cells (132, 136, 168),
their inhibition might also be detrimental to normal cells,
particularly those with a high proliferation potential, such as
bone marrow cells. Second, MLN4924 is an NAE inhibitor
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and would likely inhibit, in addition to cullin neddylation,
other cellular neddylation reactions associated with unknown
biological consequences potentially leading to normal tissue
toxicity. Of note, despite these potential tumor cell selectivity
issues, MLN4924 was well tolerated in mice (127, 145) and
demonstrated a manageable toxicity in humans (98).
It has been reported recently that cancer cells can develop
resistance to MLN4924 via selection of rare clones with
heterozygous mutations in the targeting enzyme NAEb (92,
139). Nevertheless, MLN4924, which targets multiple CRL-
associated signaling pathways, is anticipated to be more ef-
fective than targeted therapy using a single kinase inhibitor,
since human cancers often harbor multiple mutations with
alterations in multiple signaling pathways (54). To overcome
the limitations of MLN4924, future basic scientific studies
are critical to better understand how the neddylation pathway
and its key components regulate the initiation and progres-
sion of human tumorigenesis. In the context of drug discov-
ery, specific inhibitors against NEDD8 E2s (UBE2M or
UBE2F) and/or a particular E3 with known involvement in
human cancer might provide improved tumor cell selectivity
and toxicity profiles. It is highly hoped and anticipated that
with validation of NEDD8-CRLs as attractive anticancer
targets, small molecule inhibitors targeting a unique com-
ponent of the NEDD8 pathway or a specific CRL E3, known
to be activated in human cancer, will be discovered. The
development of a novel class of anticancer agents targeting
the NEDD8/CRL E3 pathway, acting either alone or in
combination with current anticancer therapies is a promising
strategy for the treatment of selected sets of cancer patients
with tumors bearing overactivation of this pathway.
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ARE¼ antioxidant response element
BCA3¼ breast cancer-associated
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neddylation-dissociated-1
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CDT1¼ chromatin licensing and DNA
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CUL1¼ cullin-1
CUL2¼ cullin-2
CUL3¼ cullin-3
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CUL7¼ cullin-7
CUL9¼ cullin-9
DCN1¼ defective in cullin neddylation 1
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DDR¼DNA damage response
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mTOR-interacting protein
E2F-1¼E2F transcription factor 1
EGFP¼ enhanced green fluorescent
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EGFR¼ epidermal growth factor
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HIF1¼ hypoxia-inducible factor-1
HIF2¼ hypoxia-inducible factor-2
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light chain 3
MDM2¼murine double minute-2
MRFAP1¼mortality factor on
chromosome 4 associated
protein 1
mTOR¼mammalian target
of rapamycin
mTORC1¼mammalian target
of rapamycin complex 1
NAE¼NEDD8-activating enzyme
NAE1¼NEDD8-activating enzyme
E1 Subunit 1
NEDD8¼ neural precursor cell
expressed, developmentally
downregulated 8
NEDP1¼NEDD8-specific protease 1
NF-jB¼ nuclear factor-jB
NRF2¼ nuclear factor
erythroid 2-related factor 2
PfUCH54¼ 54-kDa plasmodium
falciparum ubiquitin
C-terminal hydrolase
PINK1¼ PTEN induced putative
kinase 1
RBX1¼RING box protein-1
RBX2¼RING box protein-2
RCAN1¼ regulator of calcineurin 1
RING¼ really interesting new gene
RNF111¼ ring finger protein 111
ROC1¼ regulator of cullins 1
ROC2¼ regulator of cullins 2
ROS¼ reactive oxygen species
SAG¼ sensitive to apoptosis gene
SCF¼ Skp1, cullin, and F-box
protein
SENP8¼ SUMO/sentrin-specific
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SKP1¼ S-phase kinase-associated
protein 1
SKP2¼ S-phase kinase-associated
protein 2
TGFb-RII¼ transforming growth factor b
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TRIM40¼ tripartite motif containing 40
UAE¼ ubiquitin-activating enzyme
Ub¼ ubiquitin
UBA3¼ ubiquitin-like modifier
activating enzyme 3
UBC12¼ ubiquitin-conjugating
enzyme 12
UBE2F¼ ubiquitin-conjugating
enzyme E2F
UBE2M¼ ubiquitin-conjugating
enzyme E2M
UBLs¼ ubiquitin-like proteins
UCH-L1¼ ubiquitin carboxyl-terminal
esterase L1
UCH-L3¼ ubiquitin carboxyl-terminal
esterase L3
UPS¼ ubiquitin–proteasome
system
USP21¼ ubiquitin-specific peptidase 21
VHL¼ von Hippel-Lindau
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